Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Radhakrishan Gandhi

Cardiovascular Disease Newport Beach, CA Medical Doctor

NPI 1417026493 CMS profile 200068

520 Superior Ave Ste 220, Newport Beach, CA 92663

Open in the dashboard

General payments

$9,269

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12 paid to institutions, not to them · program year 2019

Through program year 2025, Radhakrishan Gandhi of Newport Beach, CA is reported in the CMS Open Payments database as having received $9,269 across 323 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,666 69
2024 General $799 42
2023 General $447 21
2022 General $2,919 87
2021 General $1,157 55
2020 General $343 15
2019 General $938 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Radhakrishan Gandhi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Radhakrishan Gandhi were reported at $2,666. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Radhakrishan Gandhi Cardiovascular Disease median Middle half National median
2019 $938 $450 $127–$1,392 $163
2020 $343 $242 $77–$751 $114
2021 $1,157 $335 $101–$1,037 $132
2022 $2,919 $395 $121–$1,211 $149
2023 $447 $443 $136–$1,283 $160
2024 $799 $450 $136–$1,323 $164
2025 $2,666 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,874 26 payments
  2. Novartis Pharmaceuticals Corporation $1,081 61 payments
  3. Amgen Inc. $695 32 payments
  4. Abiomed $576 17 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $565 31 payments
  6. E.R. Squibb & Sons, L.L.C. $312 18 payments
  7. Janssen Pharmaceuticals, Inc $304 15 payments
  8. Medtronic, Inc. $302 5 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $269 12 payments
  10. Pfizer Inc. $266 19 payments
  11. Other $2,026 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,402 311 payments
  2. Travel and Lodging $1,824 9 payments
  3. Education $43 3 payments
Products named General payments · program years 2019–2025
  1. OPTIS $1,500 11 payments
  2. ASSURITY $1,118 7 payments
  3. Impella $538 16 payments
  4. Repatha $524 25 payments
  5. LEQVIO Cardiology/Vascular Diseases $484 34 payments
  6. JARDIANCE $381 24 payments
  7. XARELTO $304 15 payments
  8. ENTRESTO $290 12 payments
  9. LifeVest $269 12 payments
  10. LEQVIO Cardiovascular $259 13 payments
  11. Other $4,207 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

5,145

Median for Interventional Cardiology: 2,236

Drug cost

$1,032,031

Median for Interventional Cardiology: $380,412

Branded share of claims

23.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 360 $439,543
Entresto Sacubitril/Valsartan Brand 132 $160,508
Xarelto Rivaroxaban Brand 107 $134,015
Farxiga Dapagliflozin Propanediol Brand 73 $72,384
Brilinta Ticagrelor Brand 76 $56,024
Multaq Dronedarone Hcl Brand 13 $30,926
Repatha Sureclick Evolocumab Brand 24 $23,675
Jardiance Empagliflozin Brand 25 $23,292
Praluent Pen Alirocumab Brand 11 $12,951
Nexletol Bempedoic Acid Brand 13 $8,101

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$413,904

Of which drugs: $294

Medicare patients

775

Average age 77

Services billed

4,978

372 women, 403 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 49%
Diabetes 35%
Heart failure 31%
Atrial fibrillation 31%
Chronic kidney disease 31%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $185
$185 25 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $120
$120 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $98
$98 107 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $46
  • PFIZER INC. $12
$58 360 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $51
$51 132 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record